Table 4.
Predictive Factors Related to Immunological Remission in 108 PLA2R Antibody-Associated MN Patients Receiving One Cycle of Rituximab Within 6 Months: Univariate Analysis
| Variable | OR (95% CI) | P-value |
|---|---|---|
| Gender (female/male) | 6.019 (1.321, 27.428) | 0.020* |
| PLA2R-Ab titer >66.3RU/mL | 0.997 (0.995, 0.999) | 0.008* |
| PLA2R-Ab titer ≤66.3RU/mL | 1 | |
| Hemoglobin (g/L) | 1.030 (1.008, 1.053) | 0.008* |
| Albumin (g/L) | 1.116 (1.038, 1.199) | 0.003* |
| Creatinine (µmol/L) | 0.994 (0.987, 1.002) | 0.148 |
| eGFR (mL/min/1.73m2) | 1.018 (1.003, 1.034) | 0.018* |
| β2-MG (mg/L) | 0.685 (0.504, 0.932) | 0.016* |
| Cystatin C (mg/L) | 1.021 (0.916, 1.136) | 0.711 |
| CD19 (per mm) | 1.002 (0.999, 1.005) | 0.122 |
| CD4 (per mm) | 1.002 (1.000, 1.003) | 0.061 |
| CD8 (per mm) | 1.002 (1.000, 1.004) | 0.072 |
Note: *Stands for p < 0.05.
Abbreviations: MN, membranous nephropathy; β2-MG, beta 2 microglobulin; CD, cluster of differentiation; eGFR, estimated glomerular filtration rate; PLA2R antibody, phospholipase A2 receptor antibody.